1. Home
  2. SNDX

SNDX

Syndax Pharmaceuticals Inc.

Logo Syndax Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 9:58am EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Founded: 2005 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 1.9B IPO Year: 2016
Target Price: $35.00 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.98 EPS Growth: N/A
52 Week Low/High: $11.22 - $25.34 Next Earning Date: 05-06-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 337.83%

Share on Social Networks: